Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lichen planus responding to efalizumab.

Markus Böhm1, Thomas A Luger

  • 1Department of Dermatology, University of Münster, Germany. bohmm@uni-muenster.de

Journal of the American Academy of Dermatology
|April 17, 2007
PubMed
Summary

Efalizumab effectively treated widespread, relapsing lichen planus (LP). This biologic medication rapidly improved both skin lesions and itching in a generalized cutaneous LP patient.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Medical care situation of people with vitiligo : A pilot and feasibility study on guideline-oriented management in German dermatology practices].

Dermatologie (Heidelberg, Germany)·2026
Same author

Epidemiology and Comorbidity of Vitiligo in Germany: A Claims Data Analysis.

Acta dermato-venereologica·2026
Same author

Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.

JAMA dermatology·2026
Same author

Validation of Self-Reported Vitiligo Prevalence among Adults in the USA and Europe Using the 2024 National Health and Wellness Survey.

Dermatology and therapy·2026
Same author

The α-MSH-MC1R Axis Modulates Sex-Specific Senescence and Inflammation Processes in Human Articular Chondrocytes and Mice Knee Joints.

Aging and disease·2026
Same author

Multilingual Digital Search Behavior Reveals Cultural Disparities in Vitiligo Information Needs in Germany.

International journal of dermatology·2026

Area of Science:

  • Dermatology
  • Immunology

Background:

  • Lichen planus (LP) is a prevalent inflammatory skin condition with an unclear etiology.
  • Generalized and recurrent cases of LP present significant therapeutic challenges.

Observation:

  • A patient with extensive, relapsing generalized LP was treated with efalizumab.
  • Treatment duration with the biologic agent was three months.

Findings:

  • Efalizumab administration led to a rapid and positive response in both pruritus and skin lesions.
  • The patient experienced prompt relief from symptoms and visible improvement in skin manifestations.

Implications:

  • Efalizumab demonstrates potential as a novel therapeutic option for cutaneous lichen planus.
  • These findings align with prior research on efalizumab's efficacy in oral erosive LP, suggesting broader applicability.

Related Experiment Videos